Company profile: Tessera Therapeutics
1.1 - Company Overview
Company description
- Provider of Gene Writing technology for permanent therapeutic alterations to the human genome, offering RNA Gene Writers to change base pairs, make small insertions, deletions or replacements, and integrate entire genes without double stranded breaks; DNA Gene Writers to durably write new DNA sequences with potential one-time cures; and a proprietary lipid nanoparticle delivery system for safe, effective nucleic acid delivery beyond the liver.
Products and services
- DNA Gene Writers: Tessera develops DNA-template-based writers that write new DNA sequences into the genome using a DNA template to durably alter DNA, offering the potential of a one-time cure
- Gene Writing Technology: Tessera engineers a genome-engineering platform to make permanent therapeutic alterations to the human genome, enabling a new category of genetic medicines with durable edits
- RNA Gene Writers: Tessera architects DSB-free writers that change base pairs, perform small insertions, deletions or replacements, and integrate entire genes into the genome
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tessera Therapeutics
Visikol
HQ: United States
Website
- Description: Provider of CRO services focused on digital pathology, 3D tissue imaging, and 3D cell culture assays/models. Delivers end-to-end 2D/3D in vitro models, tissue clearing (Visikol HISTO) and confocal microscopy, high content screening, bio-imaging, bioinformatics and image analysis, plus custom drug discovery solutions and 21 CFR Part 11 compliant digital pathology software.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Visikol company profile →
Altar
HQ: France
Website
- Description: Provider of biotechnology solutions in automated fluidics, developing and operating proprietary technologies that bring microbes to performance suitable for commercial use. Serves customers leveraging microorganisms to produce food, feed, flavors & fragrances, cosmetics, and fuels.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Altar company profile →
Bio-Rad
HQ: United States
Website
- Description: Provider of imaging systems for fast acquisition, chemiluminescence sensitivity, and fluorescent western blot detection; technologies for rapid bispecific antibody prototyping and high-throughput screening; ready-to-use specialty immunoassay controls; bioprocess data analytics tools; chromatography resources for biomolecule purification; and droplet digital PCR for cell line development, genome edit detection, and CNV analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bio-Rad company profile →
Jena Bioscience
HQ: Germany
Website
- Description: Provider of biotechnology products, including isothermal amplification and LAMP products for rapid DNA/RNA analysis, ready-to-use lyophilized PCR mixes in 96-well plates, contamination detection controls for food, cell cultures and nucleic acids, RNA/DNA preparation and cleanup kits with magnetic bead options, and click reagents for lipid and posttranslational modification analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jena Bioscience company profile →
PharmaFluidics
HQ: Belgium
Website
- Description: Provider of integrated milli- to nano-engineered solutions for mixing, separation and reaction processes, offering high-quality, tailor-made designs. Products include μPAC Neo silicon-based HPLC columns for high-resolution separations; EASY-Spray and Double nanoViper columns for nano/capillary LC-MS and robust proteomics; MAbPac RP for intact protein characterization; Accucore 150 Amide HILIC for hydrophilic biomolecules/glycans.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PharmaFluidics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tessera Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tessera Therapeutics
2.2 - Growth funds investing in similar companies to Tessera Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tessera Therapeutics
4.2 - Public trading comparable groups for Tessera Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →